Bristol-Myers Squibb Company (NYSE: BMY)’s stock price has decreased by -0.56 compared to its previous closing price of 67.48. However, the company has experienced a 0.89% gain in its stock price over the last five trading sessions. Barron’s reported on 02/02/23 that Bristol Myers Profit Tops Estimates but Revenue Falls on Lower Revlimid Sales
Is It Worth Investing in Bristol-Myers Squibb Company (NYSE: BMY) Right Now?
Bristol-Myers Squibb Company (NYSE: BMY) has a higher price-to-earnings ratio of 22.73x compared to its average ratio, and the 36-month beta value for BMY is at 0.44. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 1 rating it as “overweight,” 10 as “hold,” and 1 as “sell.”
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The average price suggested by analysts for BMY is $80.44, which is $14.37 above the current market price. The public float for BMY is 2.10B, and currently, shorts hold a 0.81% of that float. The average trading volume for BMY on March 17, 2023 was 8.30M shares.
BMY’s Market Performance
BMY’s stock has seen a 0.89% increase for the week, with a -7.13% drop in the past month and a -13.25% fall in the past quarter. The volatility ratio for the week is 2.44%, and the volatility levels for the past 30 days are at 1.78% for Bristol-Myers Squibb Company The simple moving average for the last 20 days is -2.80% for BMY stock, with a simple moving average of -8.70% for the last 200 days.
Analysts’ Opinion of BMY
Many brokerage firms have already submitted their reports for BMY stocks, with Jefferies repeating the rating for BMY by listing it as a “Hold.” The predicted price for BMY in the upcoming period, according to Jefferies is $62 based on the research report published on March 06th of the current year 2023.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see BMY reach a price target of $95. The rating they have provided for BMY stocks is “Overweight” according to the report published on January 17th, 2023.
Credit Suisse gave a rating of “Neutral” to BMY, setting the target price at $78 in the report published on November 18th of the previous year.
BMY Trading at -5.78% from the 50-Day Moving Average
After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.60% of loss for the given period.
Volatility was left at 1.78%, however, over the last 30 days, the volatility rate increased by 2.44%, as shares sank -6.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.14% lower at present.
During the last 5 trading sessions, BMY rose by +0.89%, which changed the moving average for the period of 200-days by -11.87% in comparison to the 20-day moving average, which settled at $68.82. In addition, Bristol-Myers Squibb Company saw -6.74% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMY starting from Caforio Giovanni, who sale 240,000 shares at the price of $74.65 back on Feb 06. After this action, Caforio Giovanni now owns 236,104 shares of Bristol-Myers Squibb Company, valued at $17,916,000 using the latest closing price.
Powell Ann, the EVP, Chief Human Resources of Bristol-Myers Squibb Company, sale 11,183 shares at $74.69 during a trade that took place back on Feb 06, which means that Powell Ann is holding 23,043 shares at $835,258 based on the most recent closing price.
Stock Fundamentals for BMY
Current profitability levels for the company are sitting at:
- +20.08 for the present operating margin
- +57.39 for the gross margin
The net margin for Bristol-Myers Squibb Company stands at +13.71. Equity return is now at value 19.80, with 6.40 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
In conclusion, Bristol-Myers Squibb Company (BMY) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
